scholarly journals Transcriptome Sequencing Reveals the Potential Mechanisms of Modified Electroconvulsive Therapy in Schizophrenia

2021 ◽  
Author(s):  
Wanhong Peng ◽  
Qingyu Tan ◽  
Minglan Yu ◽  
Ping Wang ◽  
Tingting Wang ◽  
...  
Keyword(s):  
Electroconvulsive Therapy ◽  
Transcriptome Sequencing ◽  
Modified Electroconvulsive Therapy

Modified Electroconvulsive Therapy Attitudes Questionnaire

2020 ◽  
Author(s):  
Lauren Alexander ◽  
Kevin Malone ◽  
Eimear Counihan ◽  
Jennifer Kennedy ◽  
Darren Roddy ◽  
...  
Keyword(s):  
Electroconvulsive Therapy ◽  
Therapy Attitudes ◽  
Modified Electroconvulsive Therapy

Efficacy and safety of modified electroconvulsive therapy for the refractory depression in older patients

2019 ◽  
Author(s):  
Xue Jiang ◽  
Qin Xie ◽  
Lian-Zhong Liu ◽  
Bao-Liang Zhong ◽  
Liang Si ◽  
...  
Keyword(s):  
Electroconvulsive Therapy ◽  
Older Patients ◽  
Depression Scale ◽  
Pressure Rise ◽  
Hamilton Depression Scale ◽  
Efficacy And Safety ◽  
Serious Adverse Events ◽  
Refractory Depression ◽  
Immediate Memory ◽  
Modified Electroconvulsive Therapy

Abstract Background: To explore the clinical efficacy and safety of modified electroconvulsive therapy (MECT) in the treatment of elderly patients with refractory depression. Methods : A total of 43 older patients (18 male and 25 female) with refractory depression were enrolled in our study from March 2014 to February 2015, with the average age of 65±4.8 years old. Modified electroconvulsive therapy (MECT) was performed in these patients after physical examinations and anesthesia procedures. Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) were used to assess the efficacy of MECT, and Wechsler Memory Scale (WMS) and mini mental state examination (MMSE) were used to evaluate the memory ability and cognitive function. The preoperative, intraoperative and postoperative care were conducted in patients accompanied by physical diseases. Results: The rate of efficacy was calculated as 67.44% after 4 weeks of MECT treatment. Our results showed HAMA and HAMD scores after 2 weeks of MECT treatment were significantly lower than that before treatment (P<0.05), and the differences were more significant after 4 weeks of MECT treatment (P<0.01). Compared with before treatment, the scores of memory quotient and immediate memory of WMS decreased significantly after 1 week of treatment (P<0.05). However, these events were not be presented with the progress of treatment, except for after 2 weeks of treatment. Our results demonstrated that compared with before treatment, the scores of MMSE significantly increased significantly after 4 weeks of treatment (P<0.05). There were no serious adverse events in all patients, including cardiovascular and cerebrovascular events. Among them, 7 patients had transient blood pressure rise and slight headache, which were relieved spontaneously after resting. Conclusion: MECT is an effective, well tolerated and safe method for the treatment of older patients with refractory depression, which is temporary and reversible for cognitive impairment. MECT can be recommended for the treatment of these patients after conducting effective risk control of comorbid somatic diseases.

Clinical Signs with Modified Electroconvulsive Therapy

1963 ◽  
Vol 109 (460) ◽  
pp. 399-403 ◽  
Author(s):  
J. G. Whitwam ◽  
T. Moreton ◽  
J. Norman
Keyword(s):  
Electroconvulsive Therapy ◽  
Muscle Relaxant ◽  
Parasympathetic Nervous System ◽  
Clinical Signs ◽  
Short Acting ◽  
Neurological Signs ◽  
Clinical Description ◽  
Modified Electroconvulsive Therapy ◽  
Acting Muscle ◽  
Stimulation Of

In many electroconvulsive therapy centres atropine is used to mitigate adverse effects resulting from stimulation of the parasympathetic nervous system, while the violence of muscular contractions is controlled with a muscle relaxant. It is customary to secure hypnosis with a short acting barbiturate prior to administration of the relaxant. The first report of the use of thiopentone for E.C.T. was by Rubinstein (1945), and methohexitone (Lilly 25398) was introduced by Friedman (1959). The use of succinylcholine (iodide) for E.C.T. was first reported by Holmberg and Thesleff (1951). The neurological signs during unmodified E.C.T. have been well documented (e.g. Klein and Early, 1948a, 1948b, 1949; Kalinowsky and Hoch, 1952). There is as yet no comparable detailed clinical description of E.C.T. when modified by atropine and a short acting muscle relaxant preceded by a barbiturate. This discussion is limited to some of those signs which may be of assistance in the management of therapy.

An Intrasubject Comparison of Two Doses of Succinylcholine in Modified Electroconvulsive Therapy

1999 ◽  
Vol 89 (5) ◽  
pp. 1301-1304 ◽  
Author(s):  
N. Murali ◽  
E. S. M. Saravanan ◽  
V. J. Ramesh ◽  
B. N. Gangadhar ◽  
N. Jananakiramiah ◽  
...  
Keyword(s):  
Electroconvulsive Therapy ◽  
Modified Electroconvulsive Therapy

The effect of modified electroconvulsive therapy on vasopressin release and haemostasis in man

1990 ◽  
Vol 1 (3) ◽  
pp. 293-298 ◽  
Author(s):  
K. K. Hampton ◽  
P. J. Grant ◽  
M. Boothby ◽  
H. G. Dean ◽  
J. A. Davies ◽  
...  
Keyword(s):  
Electroconvulsive Therapy ◽  
Vasopressin Release ◽  
Modified Electroconvulsive Therapy

The Bispectral Electroencephalogram During Modified Electroconvulsive Therapy Under Propofol Anesthesia-Relation With Seizure Duration and Awakening

2011 ◽  
Vol 27 (2) ◽  
pp. 114-118 ◽  
Author(s):  
Satinder Gombar ◽  
Deepika Aggarwal ◽  
Ashish Kumar Khanna ◽  
Kanti Kumar Gombar ◽  
Bir Singh Chavan
Keyword(s):  
Electroconvulsive Therapy ◽  
Seizure Duration ◽  
Modified Electroconvulsive Therapy
Sign in / Sign up

Export Citation Format

Share Document